Compugen (CGEN) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Compugen (CGEN) has outperformed Invivyd (IVVD) over the past year, gaining 17.1% versus a loss of 57.3%. Over five years, CGEN leads with a -66.7% price change compared with -97.8% for IVVD. Invivyd is the larger company by market cap ($206.4 million vs $200.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | IVVD |
|---|---|---|
| Share price | $2.12 | $0.7004 |
| Market cap | $200.82M | $206.45M |
| 1-day change | -1.40% | -3.87% |
| YTD return | +38.56% | -71.64% |
| 1-year return | +17.13% | -57.29% |
| 5-year return | -66.67% | -97.84% |
| P/E ratio (TTM) | 5.58 | — |
| EPS (TTM) | $0.38 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $3.07 |
| 52-week low | $1.43 | $0.528 |
| Distance from 52-week high | -34.57% | -77.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.98% | +1327.76% |
| Average volume | 244.17K | 4.78M |
| Shares outstanding | 94.72M | 294.76M |
| Employees | 75 | 122 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed IVVD by 74.4 percentage points over the past year.
- The two companies sit in different sectors: Compugen in Health Care and Invivyd in Healthcare.
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
CGEN vs IVVD FAQ
Which is bigger, Compugen or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $206.45M compared with $200.82M for Compugen (CGEN).
Which stock has performed better over the past year, CGEN or IVVD?
CGEN returned +17.13% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Compugen and Invivyd in the same industry?
No. Compugen is in the Health Care sector, while Invivyd is in Healthcare.